Portfolio company
Elypta
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
4 investors
Sectors
About
Elypta develops liquid biopsy kits and software for profiling metabolism biomarkers to enable early cancer detection for clinicians and researchers.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Elphogene
This biotechnology company develops a molecular liquid biopsy test to monitor cancer progression and treatment efficacy for oncology patients and healthcare professionals.
Epiliquid
This company develops blood-based liquid biopsy tests for early cancer detection and monitoring, serving clinical laboratories and medical practitioners.
MetaSight
MetaSight Diagnostics develops multi-omics liquid biopsy tests for the early detection of chronic and acute diseases for healthcare providers and patients.
Glycanostics
This digital health company develops non-invasive liquid biopsy tests for early-stage cancer detection, serving clinical laboratories, hospitals and oncology professionals.
Flomics
Flomics develops liquid biopsy blood tests and a bioinformatics platform for early cancer detection in clinical and research settings.
Oncoliq
This company develops liquid biopsy tests using molecular biology and machine learning for early cancer detection in clinical and screening settings.
Fyr Bio
This company develops liquid biopsy diagnostic tools and biomarkers using extracellular vesicle enrichment technology for healthcare providers and pharmaceutical researchers.
Infiniplex
This company develops liquid biopsy solutions using blood tests to monitor genetic biomarkers for cancer screening and precision oncology decisions for healthcare providers.